Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00754624 · ClinicalTrials.gov registry record · Phase 2
An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial
A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
- 20
- Study locations
NCT00754624: Completed Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Mannkind Corporation.
NCT00754624 is a Phase 2 study of Type 2 Diabetes Mellitus that has completed, run by Mannkind Corporation. The registered enrollment target is 229 participants, below the 2,958-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00754624, a Phase 2 study of Type 2 Diabetes Mellitus, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
- 20
- Study locations
Study Summary
Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005
Conditions Studied
Interventions
- DRUG Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
Study Locations (20)
Texas
- Dallas Diabetes & Endocrine Center - Dallas
- University of Texas Southwestern Medical Center - Dallas
- Texas Diabetes Institute - San Antonio
- Diabetes & Glandular Disease Research Assoc PA - San Antonio
Connecticut
- Alliance Medical Group of Greater Waterbury - Middlebury
- The Hospital of Central Connecticut - New Britain
- Soundview Research Associates - Norwalk
BGR
- MBAL "Pleven" - Pleven
- SBALENG-Sofia Institute of Endocrinology - Sofia
- MBAL Alexandrovska Hospital - Sofia
California
- Dorothy L & James E Frank Diabetes Research Institute - San Mateo
- Sansum Medical Research Institute - Santa Barbara
New York
- Diabetes Care & Information Center of New York - Flushing
- Diabetes Team Associated - New York
Florida
- University of Miami School of Medicine - Miami
Louisiana
- Oschner Clinic Foundation - New Orleans
Minnesota
- International Diabetes Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2004-05 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00754624 record still lists
NCT00754624 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, below the 2,958-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler is the first listed.
NCT00754624 names 20 study sites across 11 states, led by Texas, Connecticut, BGR.
Frequently Asked Questions
What is clinical trial NCT00754624 about?
NCT00754624 is a clinical study titled "An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial". Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005
What is the current status of trial NCT00754624?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2004-05. Estimated completion is 2008-10.
What conditions does trial NCT00754624 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT00754624?
The interventions under investigation include: Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler (DRUG).
Who is sponsoring clinical trial NCT00754624?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00754624 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00754624's enrollment target sits among peer trials
229 35th of 130 higher than 96 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia